Mitoguazone

米托胍腙

Report date: 2023/04/25 15:42:51
NME

Base Information

Drug NameMitoguazone
Drug Alias NameNSC-30609NSC-32946Win-10708-2PA-001
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionS-adenosylmethionine decarboxylase 1 inhibitors
TargetsS-adenosylmethionine decarboxylase 1
Therapy Area/IndicationsPancreatic NeoplasmsStomach NeoplasmsColorectal Neoplasms +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesColombia
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesNational Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesPontificia Universidad Javeriana
Inactive CompaniesPathologicaSanofiNational Cancer Institute +[4] 
Active IndicationsPancreatic NeoplasmsStomach NeoplasmsColorectal Neoplasms +[6] 
Inactive IndicationsLymphoma, Non-HodgkinHIV Infections

Other Information

ATC CodeL01XX16
Related LinksKEGG